Proteomics International Laboratories Ltd. (AU:PIQ) has released an update.
Proteomics International Laboratories Ltd, a leader in predictive diagnostics, has raised A$6.5 million through an institutional placement to strengthen its balance sheet and expand globally. The company is advancing its PromarkerD blood test for diabetic kidney disease towards a national launch in the USA, while also making significant progress in validating biomarker panels for its endometriosis and oesophageal cancer blood tests, PromarkerEndo and PromarkerEso. Additionally, the firm retains its key ISO 13485 certification, essential for the safety and quality of medical devices, and was granted a European patent for its OxiDx technology, further bolstering its robust pipeline of diagnostic tests.
For further insights into AU:PIQ stock, check out TipRanks’ Stock Analysis page.
